Vanguard Capital Management
ANIP icon

Vanguard Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Vanguard Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.4M Buy
838,224
+15,160
+2% +$1.22M ﹤0.01% 1759
2026
Q1 		$63.3M Buy
+823,064
New +$64.2M ﹤0.01% 1727

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management's ANIP Position: Q2 2026 in Review

Vanguard Capital Management increased its ANI Pharmaceuticals (ANIP) stake by 1.8% in Q2 2026, buying an estimated $1.22M and bringing the position to 838,224 shares worth $69.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1759.

Vanguard Capital Management first reported a position in ANIP in Q1 2026 and has held it in 2 quarters since. 306 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Vanguard Capital Management held 838,224 shares of ANI Pharmaceuticals worth $69.4M as of Q2 2026.
  • Vanguard Capital Management bought 15,160 ANI Pharmaceuticals shares in Q2 2026, an estimated $1.22M.
  • ANI Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1759 holding.
  • Vanguard Capital Management first reported a position in ANI Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 306 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.